Literature DB >> 30354212

Lp(a) [Lipoprotein(a)]-Related Risk of Heart Failure Is Evident in Whites but Not in Other Racial/Ethnic Groups.

Brian T Steffen1, Daniel Duprez2, Alain G Bertoni3, Weihua Guan4, Michael Y Tsai1.   

Abstract

Objective- Lp(a) [lipoprotein(a)] levels vary by race/ethnicity and were recently found to be associated with risk of heart failure (HF). We aimed to determine whether Lp(a)-related risk of HF is similar across different races and whether Lp(a) may further be related to HF with reduced ejection fraction or HF with preserved ejection fraction (HFpEF). Approach and Results- In 6809 participants of the MESA (Multi-Ethnic Study of Atherosclerosis), aged 45 to 84 years and free of cardiovascular disease, 308 incident HF events occurred during a median 13-year follow-up. Baseline Lp(a) concentrations were determined by immunoassay. Incident HF was adjudicated, distinguishing HF with reduced ejection fraction (ejection fraction, <45%) from HFpEF (ejection fraction, ≥45%). Cox regression assessed relations between Lp(a) and HF risk among 4 races/ethnicities. Lp(a) was examined as a continuous variable (per log unit) and using clinical cutoff values, 30 and 50 mg/dL. Lp(a) was related to greater risk of HF in whites alone: per log unit Lp(a) (hazard ratio [HR], 1.20; P=0.02); Lp(a) ≥30 mg/dL (HR, 1.69; P=0.01), Lp(a) ≥50 mg/dL (HR, 1.87; P=0.006). No significant relations were found in black, Hispanic, or Chinese participants, and significant race interactions were observed. Lp(a) was additionally related to greater risk of HFpEF in white participants: per log unit Lp(a) (HR, 1.48; P=0.001), Lp(a) ≥30 mg/dL (HR, 2.15; P=0.01), Lp(a) ≥50 mg/dL (HR, 2.60; P=0.004). Lp(a)-related risk of HF and HFpEF in whites was independent of aortic valve disease. Conclusions- In a multiethnic sample, Lp(a)-related risks of HF and HFpEF were only evident in white participants. If confirmed, these findings have implications in further Lp(a) research and clinical practice.

Entities:  

Keywords:  aortic valve; atherosclerosis; follow-up studies; heart failure; stroke volume

Mesh:

Substances:

Year:  2018        PMID: 30354212      PMCID: PMC6207211          DOI: 10.1161/ATVBAHA.118.311220

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  23 in total

1.  Features of the metabolic syndrome and diabetes mellitus as predictors of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis.

Authors:  Ronit Katz; Nathan D Wong; Richard Kronmal; Junichiro Takasu; David M Shavelle; Jeffrey L Probstfield; Alain G Bertoni; Matthew J Budoff; Kevin D O'Brien
Journal:  Circulation       Date:  2006-04-24       Impact factor: 29.690

2.  High-density lipoprotein cholesterol and particle concentrations, carotid atherosclerosis, and coronary events: MESA (multi-ethnic study of atherosclerosis).

Authors:  Rachel H Mackey; Philip Greenland; David C Goff; Donald Lloyd-Jones; Christopher T Sibley; Samia Mora
Journal:  J Am Coll Cardiol       Date:  2012-07-11       Impact factor: 24.094

3.  Use of a reference material proposed by the International Federation of Clinical Chemistry and Laboratory Medicine to evaluate analytical methods for the determination of plasma lipoprotein(a).

Authors:  S M Marcovina; J J Albers; A M Scanu; H Kennedy; F Giaculli; K Berg; R Couderc; F Dati; N Rifai; I Sakurabayashi; J R Tate; A Steinmetz
Journal:  Clin Chem       Date:  2000-12       Impact factor: 8.327

4.  Associations between lipoprotein(a) levels and cardiovascular outcomes in black and white subjects: the Atherosclerosis Risk in Communities (ARIC) Study.

Authors:  Salim S Virani; Ariel Brautbar; Brian C Davis; Vijay Nambi; Ron C Hoogeveen; A Richey Sharrett; Josef Coresh; Thomas H Mosley; Joel D Morrisett; Diane J Catellier; Aaron R Folsom; Eric Boerwinkle; Christie M Ballantyne
Journal:  Circulation       Date:  2011-11-29       Impact factor: 29.690

Review 5.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality.

Authors:  Sebhat Erqou; Stephen Kaptoge; Philip L Perry; Emanuele Di Angelantonio; Alexander Thompson; Ian R White; Santica M Marcovina; Rory Collins; Simon G Thompson; John Danesh
Journal:  JAMA       Date:  2009-07-22       Impact factor: 56.272

Review 6.  Lipoprotein (a): impact by ethnicity and environmental and medical conditions.

Authors:  Byambaa Enkhmaa; Erdembileg Anuurad; Lars Berglund
Journal:  J Lipid Res       Date:  2015-12-04       Impact factor: 5.922

7.  Multi-Ethnic Study of Atherosclerosis: objectives and design.

Authors:  Diane E Bild; David A Bluemke; Gregory L Burke; Robert Detrano; Ana V Diez Roux; Aaron R Folsom; Philip Greenland; David R Jacob; Richard Kronmal; Kiang Liu; Jennifer Clark Nelson; Daniel O'Leary; Mohammed F Saad; Steven Shea; Moyses Szklo; Russell P Tracy
Journal:  Am J Epidemiol       Date:  2002-11-01       Impact factor: 4.897

8.  Health-related quality of life and long-term morbidity and mortality in patients hospitalised with systolic heart failure.

Authors:  Jenny Berg; Peter Lindgren; Thomas Kahan; Owe Schill; Hans Persson; Magnus Edner; Märit Mejhert
Journal:  JRSM Cardiovasc Dis       Date:  2014-08-28

9.  Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort.

Authors:  Benoit J Arsenault; S Matthijs Boekholdt; Marie-Pierre Dubé; Eric Rhéaume; Nicholas J Wareham; Kay-Tee Khaw; Manjinder S Sandhu; Jean-Claude Tardif
Journal:  Circ Cardiovasc Genet       Date:  2014-04-05

10.  Predictive Value of Collagen Biomarkers for Heart Failure With and Without Preserved Ejection Fraction: MESA (Multi-Ethnic Study of Atherosclerosis).

Authors:  Daniel A Duprez; Myron D Gross; Jorge R Kizer; Joachim H Ix; William G Hundley; David R Jacobs
Journal:  J Am Heart Assoc       Date:  2018-02-23       Impact factor: 5.501

View more
  12 in total

1.  Race-Based Differences in Lipoprotein(a)-Associated Risk of Carotid Atherosclerosis.

Authors:  Brian T Steffen; George Thanassoulis; Daniel Duprez; James H Stein; Amy B Karger; Mathew C Tattersall; Joel D Kaufman; Weihua Guan; Michael Y Tsai
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-03       Impact factor: 8.311

2.  Updates on Approaches for Studying Atherosclerosis.

Authors:  Congqing Wu; Alan Daugherty; Hong S Lu
Journal:  Arterioscler Thromb Vasc Biol       Date:  2019-04       Impact factor: 8.311

3.  Lipoprotein(a) Elevation: A New Diagnostic Code with Relevance to Service Members and Veterans.

Authors:  Renata J M Engler; Emily Brede; Todd Villines; Marina N Vernalis
Journal:  Fed Pract       Date:  2019-11

4.  Lipoprotein (a) and coronary artery calcification: prospective study assessing interactions with other risk factors.

Authors:  Kwok Leung Ong; Robyn L McClelland; Matthew A Allison; Mary Cushman; Parveen K Garg; Michael Y Tsai; Kerry-Anne Rye; Fatiha Tabet
Journal:  Metabolism       Date:  2021-01-07       Impact factor: 8.694

Review 5.  The impact of race and ethnicity on lipoprotein(a) levels and cardiovascular risk.

Authors:  Gissette Reyes-Soffer
Journal:  Curr Opin Lipidol       Date:  2021-06-01       Impact factor: 4.616

6.  Risks of incident heart failure with preserved ejection fraction in Chinese patients hospitalized for cardiovascular diseases.

Authors:  Jun-Xia Zhang; Yi-Xian Liu; Chun-Lei Xia; Peng Chu; Xin-Liang Qu; Lin-Lin Zhu; Shao-Liang Chen
Journal:  J Geriatr Cardiol       Date:  2019-12       Impact factor: 3.327

Review 7.  Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?

Authors:  Natalie C Ward; Karam M Kostner; David R Sullivan; Paul Nestel; Gerald F Watts
Journal:  J Clin Med       Date:  2019-11-27       Impact factor: 4.241

8.  Association between lipoprotein (a) and heart failure with reduced ejection fraction development.

Authors:  Baoquan Wu; Zhiling Zhang; Juan Long; Hanjun Zhao; Fanfang Zeng
Journal:  J Clin Lab Anal       Date:  2021-12-01       Impact factor: 2.352

9.  Association of lipoprotein (a) and 1 year prognosis in patients with heart failure with reduced ejection fraction.

Authors:  Zhiming Li; Jingguang Liu; Jian Shen; Yumin Chen; Lizhen He; Menghao Li; Xiongwei Xie
Journal:  ESC Heart Fail       Date:  2022-04-13

10.  Association of Lipoprotein (a) variants with risk of cardiovascular disease: a Mendelian randomization study.

Authors:  Juan Xia; Chunyue Guo; Kuo Liu; Yunyi Xie; Han Cao; Wenjuan Peng; Yanyan Sun; Xiaohui Liu; Bingxiao Li; Ling Zhang
Journal:  Lipids Health Dis       Date:  2021-06-01       Impact factor: 3.876

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.